Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747922 | 0.86 | DRD2 (0.46) | DRD2DRD3FUCA1 | |
| SCHEMBL6311586 | 0.84 | KDM1A (0.47) | DRD2DRD3FUCA1KDM1ASIGMAR1 | |
| SCHEMBL6318835 | 0.84 | DRD2 (0.43) | DRD2DRD3FUCA1KDM1ASIGMAR1 | |
| SCHEMBL6326281 | 0.80 | FUCA1 (0.43) | DRD2DRD3FUCA1KDM1ASIGMAR1 | |
| SCHEMBL2803299 | 0.77 | DRD2 (0.41) | DRD2DRD3FUCA1SIGMAR1 | |
| SCHEMBL13201180 | 0.77 | DRD2 (0.41) | DRD2DRD3FUCA1SIGMAR1 | |
| SCHEMBL13196701 | 0.77 | DRD2 (0.41) | DRD2DRD3FUCA1SIGMAR1 | |
| SCHEMBL1711734 | 0.75 | FUCA1 (0.49) | FUCA1SIGMAR1 | |
| SCHEMBL5746618 | 0.74 | HSD11B1 (0.46) | DRD2DRD3FUCA1POLBGRIN2B | |
| SCHEMBL6317794 | 0.72 | FUCA1 (0.51) | FUCA1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638935-A1 | NK1 ANTAGONIST | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004110996-A1 | NK1 ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | DRD2 701/4885DRD3 948/4885FUCA1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.